scholarly article | Q13442814 |
P50 | author | Nayoung Kim | Q40152658 |
Sook-Hyang Jeong | Q88677490 | ||
P2093 | author name string | Dong Ho Lee | |
Jin-Wook Kim | |||
Young Soo Park | |||
Jin-Hyeok Hwang | |||
Jong Ho Lee | |||
Eun Sun Jang | |||
Jaihwan Kim | |||
Cheol Min Shin | |||
Kyeong Sam Ok | |||
Jung Wha Chung | |||
Gi Hyun Kim | |||
P2860 | cites work | Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis | Q24625697 |
Vitamin E and nonalcoholic fatty liver disease | Q27693883 | ||
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology | Q28267844 | ||
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults | Q29614911 | ||
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition | Q29615691 | ||
Molecular mediators of hepatic steatosis and liver injury | Q29616709 | ||
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
The natural history of nonalcoholic fatty liver disease: a population-based cohort study | Q29617161 | ||
Long-term follow-up of patients with NAFLD and elevated liver enzymes | Q29620024 | ||
Therapy of NAFLD: antioxidants and cytoprotective agents | Q30439787 | ||
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis | Q33563333 | ||
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association | Q34112671 | ||
Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation | Q34567335 | ||
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial | Q35031127 | ||
Seoul National University Bundang Hospital's Electronic System for Total Care | Q36109910 | ||
The molecular basis for oxidative stress-induced insulin resistance | Q36184182 | ||
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. | Q36952308 | ||
Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis | Q37177461 | ||
Oxidative stress and insulin resistance: the coronary artery risk development in young adults study. | Q37235949 | ||
The epidemiology of nonalcoholic fatty liver disease: a global perspective | Q37310275 | ||
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease | Q37488800 | ||
Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis | Q37841383 | ||
Features, diagnosis, and treatment of nonalcoholic fatty liver disease | Q37996848 | ||
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group | Q39605645 | ||
Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. | Q42234528 | ||
Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese | Q43662697 | ||
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome | Q43875846 | ||
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection | Q44323346 | ||
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome | Q44385945 | ||
Identification of individuals with insulin resistance using routine clinical measurements | Q45242074 | ||
Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. | Q45939192 | ||
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial | Q46216843 | ||
Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. | Q51781353 | ||
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD | Q61989968 | ||
Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease | Q79269614 | ||
Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary | Q80470858 | ||
Is vitamin E beneficial in chronic liver disease? | Q80696380 | ||
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease | Q83706587 | ||
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years | Q84484058 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | metabolic syndrome | Q657193 |
metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
fatty liver disease | Q6058862 | ||
P304 | page(s) | 379-386 | |
P577 | publication date | 2015-12-24 | |
P1433 | published in | Clinical and molecular hepatology | Q26853927 |
P1476 | title | Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study | |
P478 | volume | 21 |